International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment

PurposeThe aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI).MethodsRecommendations were based on published data through December 2015, and were developed using the system develop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Dimopoulos, Meletios A. (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 14, 2016
In: Journal of clinical oncology
Year: 2016, Jahrgang: 34, Heft: 13, Pages: 1544-1557
ISSN:1527-7755
DOI:10.1200/JCO.2015.65.0044
Online-Zugang:Verlag, Volltext: https://doi.org/10.1200/JCO.2015.65.0044
Verlag, Volltext: https://ascopubs.org/doi/10.1200/JCO.2015.65.0044
Volltext
Verfasserangaben:Meletios A. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michele Cavo, Paul G. Richardson, Philippe Moreau, Jesús San Miguel, S. Vincent Rajkumar, Brian G.M. Durie, and Evangelos Terpos

MARC

LEADER 00000caa a2200000 c 4500
001 1680016296
003 DE-627
005 20230426084700.0
007 cr uuu---uuuuu
008 191025s2016 xx |||||o 00| ||eng c
024 7 |a 10.1200/JCO.2015.65.0044  |2 doi 
035 |a (DE-627)1680016296 
035 |a (DE-599)KXP1680016296 
035 |a (OCoLC)1341249239 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Dimopoulos, Meletios A.  |e VerfasserIn  |0 (DE-588)111795188X  |0 (DE-627)871747634  |0 (DE-576)479413746  |4 aut 
245 1 0 |a International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment  |c Meletios A. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michele Cavo, Paul G. Richardson, Philippe Moreau, Jesús San Miguel, S. Vincent Rajkumar, Brian G.M. Durie, and Evangelos Terpos 
264 1 |c March 14, 2016 
300 |a 14 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 25.10.2019 
520 |a PurposeThe aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma-related renal impairment (RI).MethodsRecommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group.RecommendationsAll patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lenalidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dexamethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A). 
700 1 |a Goldschmidt, Hartmut  |d 1956-  |e VerfasserIn  |0 (DE-588)102258023X  |0 (DE-627)717003809  |0 (DE-576)365637386  |4 aut 
773 0 8 |i Enthalten in  |t Journal of clinical oncology  |d Alexandria, Va. : American Society of Clinical Oncology, 1983  |g 34(2016), 13, Seite 1544-1557  |h Online-Ressource  |w (DE-627)313116962  |w (DE-600)2005181-5  |w (DE-576)090887018  |x 1527-7755  |7 nnas  |a International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment 
773 1 8 |g volume:34  |g year:2016  |g number:13  |g pages:1544-1557  |g extent:14  |a International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment 
856 4 0 |u https://doi.org/10.1200/JCO.2015.65.0044  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://ascopubs.org/doi/10.1200/JCO.2015.65.0044  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20191025 
993 |a Article 
994 |a 2016 
998 |g 102258023X  |a Goldschmidt, Hartmut  |m 102258023X:Goldschmidt, Hartmut  |d 910000  |d 910100  |e 910000PG102258023X  |e 910100PG102258023X  |k 0/910000/  |k 1/910000/910100/  |p 7 
999 |a KXP-PPN1680016296  |e 3527307125 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Meletios A.","role":"aut","family":"Dimopoulos","display":"Dimopoulos, Meletios A."},{"given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}],"language":["eng"],"title":[{"title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","title_sort":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment"}],"origin":[{"dateIssuedDisp":"March 14, 2016","dateIssuedKey":"2016"}],"note":["Gesehen am 25.10.2019"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedDisp":"1983-","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"pubHistory":["1.1983 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairmentJournal of clinical oncology","recId":"313116962","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"language":["eng"],"part":{"pages":"1544-1557","year":"2016","issue":"13","text":"34(2016), 13, Seite 1544-1557","extent":"14","volume":"34"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}]}],"recId":"1680016296","physDesc":[{"extent":"14 S."}],"name":{"displayForm":["Meletios A. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michele Cavo, Paul G. Richardson, Philippe Moreau, Jesús San Miguel, S. Vincent Rajkumar, Brian G.M. Durie, and Evangelos Terpos"]},"id":{"doi":["10.1200/JCO.2015.65.0044"],"eki":["1680016296"]}} 
SRT |a DIMOPOULOSINTERNATIO1420